Counteracting MS neuroinflammatory demyelination by targeting microglial M1/M2 phenotypic shift and NLRP3 inflammasome pathway has received growing attention as evidenced by many studies (Aryanpour et al. 2017; Barati et al. 2019; Zhang et al. 2021). The gene discussed is NLRP3; the disease is myeloid sarcoma.